100704-10-7

Basic information

• Product Name: (2-CHLORO-PYRIDIN-4-YL)-METHANOL
• Synonyms: (2-CHLORO-PYRIDIN-4-YL)-METHANOL;(2-CHLORO-PYRIDINE-4-YL)-METHANOL;2-CHLORO-4-HYDROXYMETHYLPYRIDINE;(2-CHLORO-4-PYRIDINYL)METHANOL;BUTTPARK 154\50-15;2-Chloro-4-(hydroxymethyl)pyridine 97%;4-Pyridinemethanol,2-chloro-(6CI,9CI);2-Chloro-4-pyridinemethanol
• CAS NO: 100704-10-7
• Molecular Formula: C₆H₆ClNO
• Molecular Weight: 143.57
• EINECS: -0
• Product Categories: PYRIDINE;pharmacetical;Pyridines
• Mol File: 100704-10-7.mol
• Article Data: 37

Chemical Properties

• Melting Point: 65.5 °C
• Boiling Point: 279 °C at 760 mmHg
• Flash Point: 122.5 °C
• Appearance: /
• Density: 1.324 g/cm³
• Vapor Pressure: 0.0264mmHg at 25°C
• Refractive Index: 1.583
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: soluble in Methanol
• PKA: 13.08±0.10(Predicted)
• CAS DataBase Reference: (2-CHLORO-PYRIDIN-4-YL)-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (2-CHLORO-PYRIDIN-4-YL)-METHANOL(100704-10-7)
• EPA Substance Registry System: (2-CHLORO-PYRIDIN-4-YL)-METHANOL(100704-10-7)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36/37/38
• Safety Statements: 26-28-45
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 100704-10-7(Hazardous Substances Data)

Usage

General Description

(2-Chloro-pyridin-4-yl)-methanol is a chemical compound with the molecular formula C6H6ClNO. It is a chlorinated derivative of pyridine, a six-membered heterocyclic compound containing nitrogen in the ring structure. The presence of the chloro group in the fourth position of the pyridine ring and the attached methanol group make this compound a valuable building block for the synthesis of various pharmaceuticals, agrochemicals, and materials. It is used in the production of pharmaceutical intermediates, herbicides, insecticides, and other specialty chemicals. Additionally, its unique structure and reactivity make it a valuable reagent in organic synthesis for the creation of diverse chemical structures.

InChI:InChI=1/C7H8INO/c1-2-10-7-6(8)4-3-5-9-7/h3-5H,2H2,1H3

Upstream product

• 65287-34-5 2-chloropyridine-4-carbonyl chloride 
• 58481-11-1 methyl 2-chloroisonicotinate 
• 64-17-5 ethanol 
• 67-56-1 methanol 
• 116570-79-7 N-methoxy-2-chloropyridinium methylsulfate 
• 6313-54-8 2-chloroisonicotinic acid, 
• 54453-93-9 ethyl 2-chloroisonicotinate 
• 925-90-6 ethylmagnesium bromide 
• 101066-61-9 2-chloropyridine-4-carbaldehyde 
• 584-08-7 potassium carbonate 
• 151477-57-5 α,α,2-trichloro-4-picoline 

Downstream Products

• 123148-66-3 2-methoxy-4-(hydroxymethyl)-pyridine 
• 478962-96-8 C₅₃H₅₁ClN₆O₁₁ 
• 193001-42-2 (2-(methylamino)pyridin-4-yl)methanol 
• 680569-47-5 (2-chloropyridin-4-yl)methyl methanesulphonate 
• 101066-61-9 2-chloropyridine-4-carbaldehyde 
• 193002-33-4 4-hydroxymethyl-2-(dimethylamino)pyridine 
• 1105691-50-6 2-chloro-4-(phenoxymethyl)pyridine 
• 864757-94-8 2-chloro-4-[(4-fluorophenoxy)methyl]pyridine 
• 1418296-63-5 1-cyclopropyl-4-{4-[(3-{(Z)-1-fluoro-2-[4-(trifluoromethoxy)phenyl]vinyl}-5-methyl-1H-pyrazol-1-yl)methyl]pyridin-2-yl}piperazine 
• 1418296-64-6 1-{4-[(3-{(Z)-2-[3-chloro-4-(trifluoromethoxy)phenyl]-1-fluorovinyl}-5-methyl-1H-pyrazol-1-yl)-methyl]pyridin-2-yl}-4-cyclopropylpiperazine 
• 1418296-65-7 1-cyclopropyl-4-{4-[(3-{(Z)-1-fluoro-2-[4-(1,1,1-trifluoro-2-methylpropan-2-yl)phenyl]vinyl}-5-methyl-1H-pyrazol-1-yl)methyl]pyridin-2-yl}piperazine 
• 1418296-66-8 1-cyclopropyl-4-[4-({3-[(Z)-1-fluoro-2-{4-[1-(trifluoromethyl)cyclopropyl]phenyl}vinyl]-5-methyl-1H-pyrazol-1-yl}methyl)pyridin-2-yl]piperazine 
• 1418296-69-1 2-{4-[(Z)-2-(1-{[2-(4-cyclopropylpiperazin-1-yl)pyridin-4-yl]methyl}-5-methyl-1H-pyrazol-3-yl)-2-fluorovinyl]phenyl}-1,1,1,3,3,3-hexafluoropropan-2-ol 
• 1418296-70-4 N-{4-[(Z)-2-(1-{[2-(4-cyclopropylpiperazin-1-yl)pyridin-4-yl]methyl}-5-methyl-1H-pyrazol-3-yl)-2-fluorovinyl]benzyl}-N-isopropylpropane-2-amine 

Relevant articles and documents

Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chain.

A number of novel guanine derivatives containing heterocyclic moieties at the O6-position have been synthesized using a purine quaternary salt which reacts with alkoxides under mild conditions. Initially O6-substituents were investigated in which the benzene ring of the known agent, O6-benzylguanine, was replaced by unsubstituted heterocyclic rings. The ability of these agents to inactivate the DNA repair protein O6-alkylguanine-DNA alkyltransferase (ATase), both as pure recombinant protein and in the human lymphoblastoid cell line Raji, has been compared with that of O6-benzylguanine. The present paper focuses on O6-substituents with basic rings, and under standard conditions several of them proved more effective than benzyl for inactivation of both recombinant and Raji ATase. Among the pyridine derivatives, the 2-picolyl compound 7 is not very active in contrast to the 3- and 4-picolyl compounds, and this influenced our choice of isomers of other basic ring systems for study. Since halogen substitution in the thiophene ring considerably increased the activity (17 versus 6), similar modifications in the pyridine series were examined. The more polar O6-substituents in this study are on the whole compatible with the stereochemical requirements of the ATase protein, and their pharmacological properties may be valuable in subsequent in vivo investigations, particularly the thenyl (6), 5-thiazolylmethyl (12), 5-bromothenyl (17), and 2-chloro-4-picolyl (21) derivatives.

NAPHTHYRIDINES AS INHIBITORS OF HPK1

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

NOVEL BICYCLIC HETEROCYCLIC COMPOUND

Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.